SQI Diagnostics Hires Assay Development Specialist to Help Advance Company's
Pipeline of New Products

TORONTO, Oct. 6 /CNW/ - SQI Diagnostics Inc. (TSX-V: SQD), a medical systems automation company focused on evolving laboratory-based autoimmune biomarker testing, announced today that Dr. Jaymie Sawyer has joined the Company in the newly created role of Vice President, Research and Development.

"The addition of Dr. Sawyer in this strategic role with SQI will help accelerate our lineup of new multiplexed autoimmune products through the development process," said Claude Ricks, President and CEO of SQI Diagnostics. "As part of our growth strategy, it's essential that we have top talent such as Dr. Sawyer, who will be based in Toronto, leading the team to support the completion of our pipeline of multiplexed autoimmune products, initiate development in new market areas, and explore novel applications for our platform technology."

In her most recent role as Director, Reagent and Assay Development at BD Biosciences, Dr. Sawyer was responsible for the development of immunogens, assay standards and monoclonal antibodies, as well as the expansion of the company's menu of assays for a novel immunoassay platform.

From 2004 to 2010, Dr. Sawyer worked in various senior roles at BD Biosciences, a global medical technology company that develops, manufactures and sells instrument systems, reagents and medical devices.

Prior to that, Dr. Sawyer has worked for industry leaders in microarray and antibody development such as Dyax, where she held the role of Associate Director Research and Development; Motorola Life Sciences Research as Team Leader, Protein Bioarrays; and Boehringer Mannheim Diagnostics, where she worked as Group Leader - Antibody Engineering.

Dr. Sawyer has a PhD in Genetics from the University of Wisconsin, Madison.

SQI believes its automated technology significantly improves upon the current industry standard methods for biomarker testing, which can be inefficient and labour intensive.

The SQiDworks automated platform is used to analyze multiple-biomarkers in a fully automated 'load-and-go' process. The platform incorporates the Company's proprietary IgX-Plex(TM) technology to allow multiplexed analysis and measurement of target antibodies and antibody sub-classes.

About SQI Diagnostics

SQI Diagnostics is a medical systems company that develops proprietary technology in multiplexing, miniaturization and automation. SQI provides laboratories the ability to simultaneously analyze multiple biomarkers, deliver accurate patient results in less time, significantly reduce labour, and increase profits...All in One Drop. For more information, please visit www.sqidiagnostics.com

Certain information in this press release is based on beliefs and assumptions of the Company's senior management and information currently available to it that may constitute forward-looking information within the meaning of securities laws. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements.

This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

%SEDAR: 00021000E

For further information: Chief Financial Officer: Andrew Morris, 416.674.9500 ext. 229, [email protected]; Media and Investor Relations: Adam Peeler, 416.815.0700 ext. 225, [email protected]